PharmaCyte Biotech (PMCB) Competitors $1.64 0.00 (0.00%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestTrends PMCB vs. IOBT, ITRM, CELU, PRLD, VTVT, CASI, MAAQ, KZR, OMGA, and XCURShould you be buying PharmaCyte Biotech stock or one of its competitors? The main competitors of PharmaCyte Biotech include IO Biotech (IOBT), Iterum Therapeutics (ITRM), Celularity (CELU), Prelude Therapeutics (PRLD), vTv Therapeutics (VTVT), CASI Pharmaceuticals (CASI), Mana Capital Acquisition (MAAQ), Kezar Life Sciences (KZR), Omega Therapeutics (OMGA), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry. PharmaCyte Biotech vs. IO Biotech Iterum Therapeutics Celularity Prelude Therapeutics vTv Therapeutics CASI Pharmaceuticals Mana Capital Acquisition Kezar Life Sciences Omega Therapeutics Exicure IO Biotech (NASDAQ:IOBT) and PharmaCyte Biotech (NASDAQ:PMCB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Does the media prefer IOBT or PMCB? In the previous week, IO Biotech had 2 more articles in the media than PharmaCyte Biotech. MarketBeat recorded 3 mentions for IO Biotech and 1 mentions for PharmaCyte Biotech. PharmaCyte Biotech's average media sentiment score of 0.54 beat IO Biotech's score of 0.22 indicating that PharmaCyte Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IO Biotech 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PharmaCyte Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer IOBT or PMCB? IO Biotech currently has a consensus target price of $9.33, indicating a potential upside of 1,110.55%. Given IO Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe IO Biotech is more favorable than PharmaCyte Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IO Biotech 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00PharmaCyte Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor IOBT or PMCB? IO Biotech received 22 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users. CompanyUnderperformOutperformIO BiotechOutperform Votes2291.67% Underperform Votes28.33%PharmaCyte BiotechN/AN/A Which has stronger valuation & earnings, IOBT or PMCB? IO Biotech is trading at a lower price-to-earnings ratio than PharmaCyte Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIO BiotechN/AN/A-$86.08M-$1.37-0.56PharmaCyte BiotechN/AN/A$330K$0.533.09 Do insiders & institutionals have more ownership in IOBT or PMCB? 54.8% of IO Biotech shares are held by institutional investors. Comparatively, 34.2% of PharmaCyte Biotech shares are held by institutional investors. 2.3% of IO Biotech shares are held by insiders. Comparatively, 1.0% of PharmaCyte Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is IOBT or PMCB more profitable? PharmaCyte Biotech's return on equity of 1.38% beat IO Biotech's return on equity.Company Net Margins Return on Equity Return on Assets IO BiotechN/A -86.56% -75.24% PharmaCyte Biotech N/A 1.38%0.71% Which has more volatility & risk, IOBT or PMCB? IO Biotech has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500. SummaryIO Biotech beats PharmaCyte Biotech on 8 of the 14 factors compared between the two stocks. Ad Weiss RatingsBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.This could be his favorite coin. Get PharmaCyte Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMCB vs. The Competition Export to ExcelMetricPharmaCyte BiotechBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.43M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio2.4846.7389.8217.18Price / SalesN/A415.011,116.21116.95Price / CashN/A182.1042.8937.86Price / Book0.503.894.784.78Net Income$330,000.00-$42.21M$120.23M$225.60M7 Day Performance-4.65%-2.15%-1.92%-1.23%1 Month Performance-6.29%4.20%11.49%3.36%1 Year Performance-24.77%18.39%30.57%16.60% PharmaCyte Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMCBPharmaCyte Biotech0.9032 of 5 stars$1.64flatN/A-26.8%$11.43MN/A2.482Earnings ReportIOBTIO Biotech3.2794 of 5 stars$0.79-2.8%$9.33+1,085.9%-47.9%$51.85MN/A-0.5930News CoverageITRMIterum Therapeutics2.0497 of 5 stars$1.87+3.9%$5.00+167.4%+6.0%$51.46MN/A-0.9410CELUCelularityN/A$2.31+4.1%N/A+36.9%$50.79M$48.20M0.00220PRLDPrelude Therapeutics2.9348 of 5 stars$0.90+12.0%$4.00+346.6%-67.3%$49.29MN/A-0.52120News CoveragePositive NewsGap UpHigh Trading VolumeVTVTvTv Therapeutics2.0038 of 5 stars$15.44+2.7%$35.00+126.7%+70.4%$49.25M$2.02M-3.329Gap UpCASICASI Pharmaceuticals3.083 of 5 stars$3.15+1.3%$6.00+90.5%-59.2%$48.70M$22.06M-1.39180MAAQMana Capital AcquisitionN/A$5.99-23.2%N/A-53.4%$48.67MN/A0.001Gap UpHigh Trading VolumeKZRKezar Life Sciences3.7081 of 5 stars$6.58-2.5%$40.50+515.5%-25.0%$48.01M$7M-0.5060Analyst ForecastNews CoverageOMGAOmega Therapeutics2.0272 of 5 stars$0.86-11.7%$9.20+974.6%-62.8%$47.40M$3.09M0.00120XCURExicure0.8904 of 5 stars$18.12+4.7%N/A+2,901.6%$47.29M$28.83M-9.2750News CoverageGap Up Related Companies and Tools Related Companies IOBT Competitors ITRM Competitors CELU Competitors PRLD Competitors VTVT Competitors CASI Competitors MAAQ Competitors KZR Competitors OMGA Competitors XCUR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PMCB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
